Correspondence 0001493152-24-031391 from AIxCrypto Holdings, Inc. (AIXC)
AIxCrypto Holdings, Inc.
Date: Aug. 12, 2024 · CIK: 0001460702 · Accession: 0001493152-24-031391
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272623
Letter
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300
Carlsbad, California 92008
August 12, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama, Jason Drory
Re: Withdrawal of Acceleration Request on the Registration Statement on Form S-1 (File No. 333-272623)
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on August 12, 2024, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Thursday, August 12, 2024, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding this matter, please do not hesitate to contact our counsel, Sichenzia Ross Ference Carmel LLP, by calling Ross D. Carmel, Esq. at 646-838-1310.
If you have any questions regarding this matter, please do not hesitate to contact Ross D. Carmel, Esq. at the number above.
Very
truly yours,
Qualigen
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Qualigen
Therapeutics, Inc.
5857 Owens Avenue, Suite 300
Carlsbad,
California 92008
August
12, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division of Corporation Finance
100
F Street, N.E.
Washington, D.C. 20549
Attn:
Doris Stacey Gama, Jason Drory
Re:
Withdrawal
of Acceleration Request on the Registration Statement on Form S-1 (File No. 333-272623)
Ladies
and Gentlemen:
Reference
is made to our letter, filed as correspondence via EDGAR on August 12, 2024, in which we requested the acceleration of the effective
date of the above-referenced Registration Statement for Thursday, August 12, 2024, at 4:00 p.m. Eastern Time, in accordance with Rule
461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective
at this time, and we hereby formally withdraw our request for acceleration of the effective date.
If
you have any questions regarding this matter, please do not hesitate to contact our counsel, Sichenzia Ross Ference Carmel LLP, by calling
Ross D. Carmel, Esq. at 646-838-1310.
If
you have any questions regarding this matter, please do not hesitate to contact Ross D. Carmel, Esq. at the number above.
Very
truly yours,
Qualigen
Therapeutics, Inc.
By:
/s/
Michael S. Poirier
Michael
S. Poirier
Chief
Executive Officer and Chairman of the Board